Study title: A 6-Week, Double-Blind, Placebo-Controlled, Parallel-Group Randomized-Withdrawel Study to Evaluate the Continued Efficacy of Modafinil at Dosages Up to 425 mg/day in Patients with Attention-Defizit/Hyperactivity Disorder who are Resonders to Modafinil Treatment, Followed by a 12-month Open-Label Extension Period.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Nervous System Diseases | |||||
Brands: | |||||
MAH holders: | |||||
Assessment: | |||||
Active substance: MODAFINIL | |||||
ATC code: | |||||
Document link: EUdraCT_reduced_datafields_for_Interim_publication-Modafinil.xls | |||||
Document date: 2011-09-19 | |||||
Study number: C1538/3048/AD/US | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |